Epredia’s E1000 Dx Digital Pathology Solution Wins 2025 International Scanner Benchmark Awards from the Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA)

September 29, 2025

RUNCORN, United Kingdom--(BUSINESS WIRE)--The Ecosystem for Pathology Diagnostics with AI Assistance (EMPAIA), an international organization that advances the use of validated AI solutions in clinical practice, has announced that Epredia, a global leader in precision cancer diagnostics, has won three categories in the 2025 International Scanner Benchmark (ISB) for Epredia’s E1000 Dx Digital Pathology Solution. The ISB recognizes excellence in quality, throughput, and design of digital slide scanning technology for pathology.

The E1000 Dx consists of a high-speed, automated, whole-slide imaging digital scanner with medical grade viewer and advanced image management and viewer software that creates high-resolution digital images of up to 1,500 tissue samples daily. The E1000 Dx is designed to maximize laboratory throughput and efficiency with technology advancements in sample detection and quality control procedures, which has the potential to make diagnostics more efficient and accurate.

EMPAIA supports regulatory, legal, technical, and organizational pathways to the adoption of validated and certified AI solutions. Through the ISB, EMPAIA seeks to identify the pathology industry’s top image-based diagnostics technologies, which provide detailed digital images that are critical inputs for potential future AI-powered diagnostics.

Epredia’s E1000 Dx won the 2025 ISB in the categories of Quality for digital images at 20x magnification, and Quality and High Throughput for digital images at 40x magnification, the highest level of magnification tested. The honors were based on a comprehensive and objective scanner evaluation, performed on samples from a variety of laboratories across Europe and reviewed by a panel of pathologists. Winners were awarded at the 37th European Congress of Pathology in Vienna, Austria, in September.

Epredia’s E1000 Dx builds on technology originally developed by 3DHISTECH, a leading pathology and diagnostics company and close commercial partner of Epredia. 3DHISTECH also received top honors in the ISB for its Pannoramic 480 Dx digital slide scanner, in the categories of High Throughput for digital images at 20x magnification and Technical capabilities, as well as being recognized with the prestigious Innovator 2025 Award. Epredia is a distributor of the full 3DHISTECH digital pathology portfolio including the Pannoramic 480 Dx.

Steven Lynum, President of Epredia, said, "Digital pathology is the future of cancer diagnostics. As pathology laboratories face greater pressure to speed up processes and reduce costs, we are deeply honored that EMPAIA has recognized the E1000 Dx as a leader in both high throughput and quality. AI holds tremendous potential to enhance the way conditions like cancer are diagnosed and ultimately treated, but AI is only as powerful as the images available to analyze. We look forward to Epredia and 3DHISTECH solutions helping laboratories maximize their digital pathology investment today as well as the potential of this technology to support AI-powered diagnostics in the future."

关于 Epredia

Epredia是解剖病理学领域的全球领导者，为癌症精准诊断和组织诊断提供全面的解决方案。Epredia拥有Erie Scientific、Menzel-Gläser、Microm、Shandon和Richard-Allan Scientific等主要品牌，产品组合包括显微镜载玻片、仪器和耗材。Epredia 是 PHC Holdings 于 2019 年收购赛默飞世尔科技公司解剖病理学业务后成立的。Epredia在美国、英国、德国、瑞士和中国的主要基地开展业务，共有约1200名员工。Epredia 致力于通过提高全球患者的癌症诊断水平来实现改善生活的使命。欲了解有关 Epredia 及其产品的更多信息，请访问www.epredia.com。

中国医学科学院肿瘤医院

关于PHC控股公司（PHC集团）

PHC Holdings Corporation（东京证券交易所股票代码：6523）是一家全球性医疗保健公司，其使命是通过具有积极影响并能改善人们生活的医疗保健解决方案为社会健康做出贡献。其子公司（统称为 PHC 集团）包括 PHC Corporation、Epredia、Ascensia Diabetes Care、LSI Medience Corporation、Mediford 和 Wemex。这些公司共同开发、生产、销售和服务糖尿病管理、医疗保健解决方案、生命科学和诊断解决方案。PHC 集团 2022 财年的合并净销售额为 3,564 亿日元，产品和服务遍布全球 125 个国家。

欲了解更多信息，请联系：

Julia Cottrill
PHC 集团企业传讯部
电子邮件：julia.cottrill@phchd.com